MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)

• Status: Completed
• Trial end date: 2004-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The clinical study evaluates the efficacy and safety of MK0476 in adult patients with allergic rhinitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Adult patients with seasonal allergic rhinitis

Exclusion Criteria:

• Patients who have nasal diseases (e.g., nasal polyp, septonasal arcuation, hypertrophic rhinitis), upper respiratory infection, sinusitis, infectious rhinitis, ocular infection and those disease severe enough to interfere with assessment of effectiveness

• Patients who have rhinitis medicamentosa, or nonallergic rhinitis (e.g., vasomotor rhinitis, eosinophilia rhinitis)

• Patient has a disease of the cardiovascular, hepatic, renal, hematologic systems, or other severe disease